DE60128084D1 - Verwendung von inaktives cln2 proenzym zur behandlung von lincl - Google Patents

Verwendung von inaktives cln2 proenzym zur behandlung von lincl

Info

Publication number
DE60128084D1
DE60128084D1 DE60128084T DE60128084T DE60128084D1 DE 60128084 D1 DE60128084 D1 DE 60128084D1 DE 60128084 T DE60128084 T DE 60128084T DE 60128084 T DE60128084 T DE 60128084T DE 60128084 D1 DE60128084 D1 DE 60128084D1
Authority
DE
Germany
Prior art keywords
cln2
proenzym
lincl
inactive
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60128084T
Other languages
English (en)
Other versions
DE60128084T2 (de
Inventor
Peter Lobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of DE60128084D1 publication Critical patent/DE60128084D1/de
Application granted granted Critical
Publication of DE60128084T2 publication Critical patent/DE60128084T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Optical Integrated Circuits (AREA)
  • Medicinal Preparation (AREA)
DE60128084T 2000-05-11 2001-05-11 Verwendung von inaktivem CLN2-Proenzym zur Behandlung von LINCL Expired - Fee Related DE60128084T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20340700P 2000-05-11 2000-05-11
US203407P 2000-05-11
US09/852,918 US20020006400A1 (en) 2000-05-11 2001-05-10 Recombinant human CLN2 protein and methods of its production and use
PCT/US2001/015386 WO2001085200A2 (en) 2000-05-11 2001-05-11 Recombinant human cln2 protein and methods of its production and use
US852918 2010-08-09

Publications (2)

Publication Number Publication Date
DE60128084D1 true DE60128084D1 (de) 2007-06-06
DE60128084T2 DE60128084T2 (de) 2008-01-03

Family

ID=26898578

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128084T Expired - Fee Related DE60128084T2 (de) 2000-05-11 2001-05-11 Verwendung von inaktivem CLN2-Proenzym zur Behandlung von LINCL

Country Status (10)

Country Link
US (5) US20020006400A1 (de)
EP (1) EP1292326B1 (de)
JP (1) JP4843774B2 (de)
AT (1) ATE360438T1 (de)
AU (1) AU2001263085A1 (de)
BR (1) BR0110746A (de)
CA (1) CA2408380C (de)
DE (1) DE60128084T2 (de)
MX (1) MXPA02011162A (de)
WO (1) WO2001085200A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
ES2432653B1 (es) * 2012-05-23 2015-09-17 Centro De Investigacion Biomedica En Red De Enfermedades Raras Un procedimiento y kit para el diagnostico diferencial de una enfermedad que cursa con afectación muscular.
TWI752907B (zh) 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
CA3152521A1 (en) * 2019-08-29 2021-03-04 Biomarin Pharmaceutical Inc. Methods for treating cln2 disease in pediatric subjects

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302685B1 (en) * 1997-09-16 2001-10-16 University Of Medicine And Dentistry Of New Jersey Human lysosomal protein and methods of its use

Also Published As

Publication number Publication date
US20090022701A1 (en) 2009-01-22
CA2408380A1 (en) 2001-11-15
US7811559B2 (en) 2010-10-12
EP1292326A2 (de) 2003-03-19
CA2408380C (en) 2012-04-17
EP1292326B1 (de) 2007-04-25
DE60128084T2 (de) 2008-01-03
ATE360438T1 (de) 2007-05-15
JP2004519415A (ja) 2004-07-02
US20120014935A1 (en) 2012-01-19
JP4843774B2 (ja) 2011-12-21
US8029781B2 (en) 2011-10-04
US20110014172A1 (en) 2011-01-20
AU2001263085A1 (en) 2001-11-20
US20020006400A1 (en) 2002-01-17
BR0110746A (pt) 2003-07-22
US8277800B2 (en) 2012-10-02
US20130273018A1 (en) 2013-10-17
WO2001085200A2 (en) 2001-11-15
MXPA02011162A (es) 2003-07-28
WO2001085200A3 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE254461T1 (de) Behandlung von augenschmerzen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE324908T1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE298246T1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE69924979D1 (de) Behandlung von chronischen schmerzen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE354361T1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE60119285D1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
ATE486594T1 (de) Methode zur behandlung von herzinsuffizienz

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee